Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension (SCOBA-PH)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01330108
First received: April 4, 2011
Last updated: July 17, 2014
Last verified: June 2014

April 4, 2011
July 17, 2014
May 2011
June 2012   (final data collection date for primary outcome measure)
Number of Subjects Not Able to Tolerate Ambrisentan [ Time Frame: baseline to 12 weeks ] [ Designated as safety issue: Yes ]
If a subject was not able tolerate ambrisentan, subject was returned to use of bosentan and ambrisentan was withdrawn within first 12 weeks of start. A subject was considered to not be able to tolerate ambrisentan if they experienced an adverse event or side effect that was not acceptable to the subject.
Safety and tolerance [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Advantage for changing from bosentan to ambrisentan would be the lack of an increase in liver function test results.
Complete list of historical versions of study NCT01330108 on ClinicalTrials.gov Archive Site
Mean Change in Distance for a Six Minute Walk at 12 Weeks Post Start of Ambrisentan [ Time Frame: baseline to 12 weeks ] [ Designated as safety issue: No ]
Evaluate the change in exercise tolerance. Measured the distance a subject was capable of walking in 6 minutes at basline compared to the distance at 12 weeks. The distance was measured in meters. A postive result reflects the distance increased at 12 weeks, a negative result reflects how much shorter the distance was.
Six minute walk testing [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Evaluate the change in exercise tolerance
Not Provided
Not Provided
 
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension

The primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.

The therapy of pulmonary arterial hypertension (PAH) has been revolutionized with the development and subsequent instruction of oral endothelin receptor antagonists (ERA). The first approved ERA, bosentan (Tracleer, Actelion, Inc.) is an effective drug widely used throughout the world in the therapy of PAH. Newer ERA's, with purported advantages over the first approved drug have since been tested and subsequently been approved for the therapy of PAH in the USA and other countries including ambrisentan (Letairis, Gilead Sciences, Inc.). However, there is little data available on the efficacy, safety and tolerability of the elective change from oral bosentan to oral ambrisentan in PAH.

Interventional
Phase 4
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Pulmonary Arterial Hypertension
Drug: ambrisentan
ambrisentan 2.5mg, 5mg, & 10mg. Daily dosage.
Other Name: Letairis
Experimental: Ambrisentan
patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
Intervention: Drug: ambrisentan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients followed routinely in the pulmonary vascular disease clinic at the University of Alabama in Birmingham, greater than or equal to 19 years of age.
  2. World Health Organization (WHO) PAH Type I
  3. WHO class I-IV symptoms (no functional class exclusion).
  4. On bosentan, twice a day, with a maximum daily dose of 250mg, on a stable dose for 3 months with no clinical indication to discontinue the drug (i.e., increased liver function studies or other intolerance). Patients may be on other drug therapies for PAH, and also may be on oxygen therapy (intermittent or continuous).

Exclusion Criteria:

  1. Known intolerance or allergy to ambrisentan.
  2. Prior therapy with ambrisentan.
  3. Current therapy with two phosphodiesterase-5 inhibitors.
  4. Change in other approved therapy for PAH (including phosphodiesterase-5 inhibitors and prostanoids) within 4 weeks of baseline study visit.
  5. Planned addition of prostanoid for clinical reasons within 3 months of baseline study visit.
  6. Active participation in another clinical study involving the medical therapy of PAH.
  7. Uncontrolled systemic hypertension or angina pectoris
  8. Serum creatinine greater than 2.5 at or within 4 weeks of baseline.
  9. Serum liver function studies greater than 3 x normal at or within 4 weeks of baseline study visit.
  10. In the opinion of the investigator, a change in PAH therapy would present significant risk to the subject.
  11. In the opinion of the investigator, the participant is unlikely to survive for 12 weeks after study entry.
  12. In the opinion of the investigator, the participant is likely to undergo lung or heart-lung transplantation within 12 weeks of study entry.
  13. A woman of childbearing potential who is not using an acceptable form of contraception.
  14. Pregnancy.
  15. In the opinion of the investigator, a participant who is not capable or willing to follow the study procedures.
Both
19 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01330108
SCOBA-PH
No
University of Alabama at Birmingham
University of Alabama at Birmingham
Not Provided
Principal Investigator: Robert C Bourge, MD Univerisity of Alabama at Birmingham
University of Alabama at Birmingham
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP